Hepatitis/MASH

The agency is slated to review the new drug application within a 6-month timeframe.

Historical comparison shows advantage in virologic response for patients with genotype 1 hepatitis C.

New drugs help prevent needless HCV-related deaths.

Interferon-free, all-oral drug regimens result in high rates of sustained virologic response for patients co-infected with hepatitis C virus and HIV.

Many patients with non-alcoholic fatty liver disease also have low vitamin D levels.

This continuing education activity is supported by educational grants from Bristol-Myers Squibb and Gilead Sciences, Inc.

Viekira Pak is an all-oral regimen that has been approved by the FDA for the treatment of genotype 1 chronic hepatitis C virus infection.

Patients with hepatitis C benefit from a collaborative approach that involves specialty pharmacists and other care providers working with patients to promote patient engagement, adherence to therapy, and management of comorbidities.

In 2014, the FDA approved notable new therapies for the treatment of cancer, bleeding disorders, inflammatory conditions, cystic fibrosis, pulmonary fibrosis, HIV, hepatitis C, multiple sclerosis, angioedema, and other conditions.

As costly new specialty medications come to market, the role of the payer in controlling formularies is becoming increasingly apparent.

Genomic sequencing reveals effect of hepatitis on genetic mutations in tumors.

A recent study has identified how chronic hepatitis infection can pave the way to liver cancer.

Kidneys transplanted from infant who died days after birth.

Popularity of new treatments lead to shrinking demand for Merck's Victrelis.

Study warns there is no testing to support a net clinical benefit.

Walgreens official discusses programs and techniques for improving patient adherence.

Thirty-eight of 40 hepatitis C patients treated with 3-drug combination cured in a recent trial.

CVS and Prime Therapeutics agreements follow Express Scripts in hepatitis C formulary updates.

AbbVie and Gilead are fighting over hepatitis C drug market share.

Attacking protein could potentially treat a number of conditions, including the Ebola virus, brain cancer, and hepatitis.

Eric Tichy, PharmD, BCPS, FCCP, senior clinical pharmacy specialist at Yale New-Haven Hospital, explains how hepatitis C therapies are changing patient treatment.

Hepatitis B vaccination reduces incidence of primary liver cancer by 84% later in life, study finds.

Valeant Pharmaceuticals of Bridgewater, NJ, has issued a voluntary recall of one lot of Virazole®(ribavirin powder for solution), 100 mL, 6g vial, 4-pack to the user level.

Valeant Pharmaceuticals is voluntarily recalling a lot of its ribavirin powder for solution (Virazole) to the user level due to microbial contamination.

Between 50% to 70% of patients with HCV show no symptoms and may not know they have the disease.

Increase found in the number of eligible hepatitis C patients being treated following approval of new treatments.

Raulo Frear, PharmD, general manager of OmedaRx, discusses the high initial cost of hepatitis C drugs like Sovaldi compared with the long term cost of treating the disease.

Express Scripts strikes a deal with AbbVie to provide its hepatitis C treatment to members at a discounted rate. But will this deal end up costing more in the end?

A new study has revealed that many patients infected with the hepatitis C virus do not seek treatment and become lost in the different stages of health care to manage the disease.